The bold move by Semler Scientific to scoop up Bitcoin as a treasury asset feels like a wild gamble straight out of a sci-fi novel, yet here they are, diving headfirst into the digital gold rush.
Picture a boardroom, stale coffee lingering in the air, where suits debate not just medical tech but digital coins that exist only in cyberspace.
It’s a jarring clash—old-school healthcare meeting futuristic finance.
Between February 14 and April 24, 2025, they snapped up 111 Bitcoins for $10 million, averaging $90,124 per coin, fees included.
That’s on top of their earlier haul of 871 Bitcoins for $88.5 million.
Crazy? Maybe. Bold? Definitely.
Now, their total stash sits at 3,303 Bitcoins, bought for $290.4 million, with a market value of $309.1 million as of April 24, 2025.
That’s an unrealized gain of $18.7 million, a number that might make even the most stoic accountant raise an eyebrow over their dusty ledger.
Unlike traditional currencies that can be freely printed, Bitcoin’s fixed supply makes it an increasingly valuable asset over time.
Semler started this journey in May 2024, dropping $40 million on 581 Bitcoins, declaring it their primary treasury reserve.
They see it as a shield against inflation, a digital safe haven—gold, but without the weight of a vault.
Imagine hauling invisible treasure, untouchable yet tracked on a glowing screen.
It’s a head-scratcher, contrasting sharply with their core gig of testing for chronic diseases with tools like QuantaFlo®.
Funding this crypto spree isn’t pocket change.
They’ve used cash flow, stock offerings, even convertible notes worth $85 million in January 2025.
Their latest ATM equity offerings have also fueled this strategy, raising net proceeds of over $128 million through stock sales by April 24, 2025.
This aggressive strategy has boosted their holdings significantly, with a net increase of 1,005 BTC since December 31, 2024.
It’s like watching a grandpa trade his savings bonds for a flashy new gadget—risky, yet oddly thrilling.
Their “BTC Yield” KPI boasts a 23.5% gain year-to-date through April 2025, a fancy way to say, “Hey, this might just work.”
Investors seem to nod along, with stock bumps like a 3% rise after the latest buy.
Still, one wonders if this pivot overshadows their medical roots.
Semler insists it’s a side hustle, not a replacement.
Balancing test tubes and blockchain, they stride into uncharted territory, leaving skeptics to sip their coffee and mutter, “What’s next?”
